Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECOVER-SLEEP: Melatonin and Tailored Lighting for Long COVID Sleep Disturbances
NCT06404112Phase 2Completed
- Sponsor
- Duke University
- Start
- Jul 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of melatonin in post-COVID-19 condition (PCC) and sleep disorder (4 arms), sponsored by Duke University. Primary endpoints: Change in total score of the PROMIS 8b SD to assess sleep disturbance at Day 63 and Change in sleep onset variability, assessed using a wearable device at Day 63. Started Jul 2024; status: completed.
02
Drugs
melatonin
03
Conditions
post-COVID-19 condition (PCC)sleep disorder
Beyond the preview
Go deeper on NCT06404112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06404112.